

# VIPS: Next steps post prioritisation

DCVMN AGM

Marion Menozzi-Arnaud, Gavi

Birgitte Giersing, WHO

November 2020

# Objective of this presentation



Following the Webinar presentation in July 2020 on the prioritisation process and final outcomes:

- Provide clarity on the next steps for VIPS and communicate the key assumptions related to the longer-term vision for use of these innovations.

# 3 innovations have been prioritised by VIPS, which could also facilitate RI catch up/ recovery from Covid-19



**Microarray patches (MAPs)**

Potential to **address most immunisation barriers** identified by countries and applicable to several use cases

Broad applicability **across life course and outbreak response**



**Heat stable formulations, including CTC**

Thermostability identified as the **top priority by countries**

**Synergies** with other innovations, i.e. MAPs, VVM-Tis, dual chamber delivery devices, SDIs

SDI: solid dose implant; VVM-Ti: Combined Vaccine Vial Monitor and Threshold Indicator



**Barcodes on primary packaging**

**Greater accuracy in tracking** at lower levels of distribution

Accelerate transition to **electronic record keeping**

# These priority innovations could also be highly relevant for COVID-19 vaccines



## Microarray patches (MAPs)

- Potential for **easier and safer administration**
- Potential for **thermostability**
- May enable **dose sparing**
- Reduced **wastage**
- Potentially increased **acceptability**



## Heat stable formulations, including CTC

- Potential to improve coverage and equity by **easing logistics for outreach (CTC)**
- Reduce vaccine **damage and wastage** due to heat/freeze exposure
- Further reduce CTC training/ logistics needs with the **VVM-TI**



## Barcodes on primary packaging

- Track and trace to **reduce stockouts and wastage**
- Monitor **coverage and AEFIs** through more accurate patient recordkeeping

...however, they may not be available for first generation vaccines



### Microarray patches (MAPs)

- **Preclinical studies** with various COVID-19 vaccines
- **Not** currently produced at **commercial scale**
- **No licensed** MAP vaccines
- **Lack of familiarity** with MAPs at programme level



### Heat stable formulations, including CTC

- **Few** of the vaccine candidates are currently **thermostable above 2-8°C**
- Current **priorities** for Covid-19 vaccines are **safety, efficacy and dose regimen**
- Heat stable formulations likely to be for next generation vaccines




### Barcodes on primary packaging

- **No global mandatory policy** in place
- **Several initiatives underway** to implement the use of barcodes on 2° and 1° packaging
- **Opportunity to leverage momentum** for policy generation and to build country capacity

# So what next?

## The innovation conundrum



# VIPS vision and mission



VIPS Vision

The VIPS Alliance aims to **create the environment** needed to position **vaccine product innovations** to be **fundamental transformation drivers** of the coverage and equity agenda, in LMICs.

---



VIPS Mission

To achieve this, the VIPS Alliance initiative will:

1. Create **alignment** on priority vaccine product innovations that have the potential to overcome country immunisation barriers and transform immunisation delivery and practices;
2. **Seek to accelerate** their **development and uptake**.

# VIPS is now creating 5-year action plans to advance the prioritised innovations



## Assessment and landscaping:

- Key challenges, bottlenecks and needs related to product innovations' development and uptake
- Existing initiatives
- Gaps

## Defining end-to-end strategies to accelerate development and uptake:

- Priority activities for the next 5 years – per innovation and cross-cutting
- Roles and responsibilities
- Funding
- Timelines


- Interviews with manufacturers, developers and implementation partners
- Joint VIPS Alliance action plan

VIPS partners are best placed to undertake these activities and will assess what each organisation can deliver and potentially engage beyond VIPS partners to ensure appropriate resources.

# The VIPS Theory of Change: Addressing the innovation conundrum through a holistic and integrated approach



- Use cases & demand sizing
- Economic evaluation, impact modelling & TSE<sup>2</sup>
- Value propositions
- Regional / country engagement
- Engagement with policy-makers



- Procurement mechanism & pot. incentives
- Funding
- Regulatory support and engagement with regulators

- Implementation research

- *Landscaping of country needs<sup>1</sup>*

- *Prioritisation<sup>1</sup>*
- TPPs

<sup>1</sup> Wholly or partially already addressed by VIPS

<sup>2</sup> Total Systems Effectiveness

# Key principles and assumptions behind VIPS



- **Novel vaccine product innovations** and approaches are needed to support the Alliance's **coverage and equity** goals.
- These innovations will have **higher commodity costs** than current presentations. The beneficial **trade-offs** in terms of increased vaccine reach and delivery savings will need to be quantified.
- To support the uptake of these innovations, the **policy, procurement and delivery environment** will need to evolve to support:
  - **Differentiated presentations** within e.g. a single country or region
  - Procurement of products with a **price premium**
  - Country **selection and implementation** of differentiated products.
- **Co-ordinated and end-to end strategies** will be needed to advance those innovations and support country uptake.
- Innovations **without a potential dual market** in HICs may require **strong incentives**.

Let us know if you have  
comments or questions!